Mirum Pharmaceuticals (NASDAQ:MIRM) Director Patrick Heron Purchases 131,425 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Patrick Heron purchased 131,425 shares of the firm’s stock in a transaction on Friday, January 23rd. The stock was bought at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the acquisition, the director owned 459,010 shares in the company, valued at $31,433,004.80. This trade represents a 40.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mirum Pharmaceuticals Trading Up 2.4%

NASDAQ MIRM opened at $99.27 on Wednesday. The company’s fifty day simple moving average is $78.36 and its 200-day simple moving average is $71.54. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $99.44. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The stock has a market cap of $5.10 billion, a P/E ratio of -115.43 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. During the same period last year, the business earned ($0.30) EPS. The business’s revenue was up 47.1% on a year-over-year basis. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. MCF Advisors LLC boosted its stake in Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares during the period. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $33,000. Quarry LP acquired a new position in Mirum Pharmaceuticals during the 3rd quarter valued at approximately $41,000. CWM LLC boosted its position in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the period. Finally, Comerica Bank grew its stake in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the last quarter.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron purchased 131,425 shares at $68.48 (≈$9.0M), increasing his stake by ~40%, a strong insider vote of confidence in the company and its valuation. Director Form 4
• Positive Sentiment: HC Wainwright upgraded MIRM to Buy, raised the price target from $102 to $130 and published an aggressive FY2030 EPS projection ($6.16), signaling bullish long‑term expectations from a coverage analyst and supporting higher share valuations. HC Wainwright Coverage
• Positive Sentiment: Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare-disease pipeline and global footprint—an acquisition likely viewed as strategically accretive and supportive of future revenue growth. Acquisition Announcement
• Positive Sentiment: Coverage and market reaction have pushed MIRM to a new 52‑week high following the analyst upgrade, which can attract momentum/technical buyers. 52‑Week High Article
• Negative Sentiment: CEO Christopher Peetz sold 6,831 shares at ~$96.19 (~$657K), reducing his stake by ~3.9%. CEO Form 4
• Negative Sentiment: Other senior exec sales the same day: COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares) and SVP Jolanda Howe (842 shares) — these reduce insider holdings and may concern some investors about near‑term insider liquidity. COO Form 4 CFO Form 4 SVP Form 4

Analyst Ratings Changes

A number of equities research analysts have weighed in on MIRM shares. HC Wainwright raised their price objective on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Stifel Nicolaus lifted their price target on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Morgan Stanley upped their price target on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Finally, Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $104.92.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.